Eli Lilly and Co. (NYSE:LLY) has been assigned a $73.00 price objective by investment analysts at Morgan Stanley in a report issued on Thursday. The brokerage presently has a “hold” rating on the stock. Morgan Stanley’s price target suggests a potential upside of 5.61% from the company’s current price.
Several other equities analysts have also recently weighed in on the company. Goldman Sachs Group Inc. upgraded Eli Lilly and from a “neutral” rating to a “buy” rating and raised their price target for the company from $89.00 to $95.00 in a report on Tuesday, September 27th. Zacks Investment Research cut Eli Lilly and from a “buy” rating to a “hold” rating in a report on Thursday, August 4th. Jefferies Group restated a “buy” rating and set a $105.00 price target on shares of Eli Lilly and in a report on Wednesday, September 14th. Argus lifted their target price on Eli Lilly and from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Tuesday, August 2nd. Finally, JPMorgan Chase & Co. upgraded Eli Lilly and from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $92.00 to $95.00 in a report on Thursday, September 8th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $92.34.
Shares of Eli Lilly and (NYSE:LLY) traded up 1.65% during trading on Thursday, hitting $69.12. The company had a trading volume of 8,620,682 shares. Eli Lilly and has a 52 week low of $64.18 and a 52 week high of $88.16. The company has a market capitalization of $73.11 billion, a P/E ratio of 30.07 and a beta of 0.28. The stock’s 50-day moving average price is $76.69 and its 200 day moving average price is $77.92.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 25th. The company reported $0.88 earnings per share for the quarter, missing the consensus estimate of $0.96 by $0.08. The firm had revenue of $5.19 billion for the quarter, compared to analysts’ expectations of $4.23 billion. Eli Lilly and had a net margin of 11.73% and a return on equity of 23.71%. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.89 EPS. On average, equities research analysts forecast that Eli Lilly and will post $3.55 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 9th. Investors of record on Tuesday, November 15th will be paid a dividend of $0.51 per share. The ex-dividend date of this dividend is Thursday, November 10th. This represents a $2.04 annualized dividend and a yield of 2.95%. Eli Lilly and’s dividend payout ratio (DPR) is 88.70%.
In related news, insider Maria A. Crowe sold 2,248 shares of the business’s stock in a transaction on Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total transaction of $182,919.76. Following the transaction, the insider now directly owns 94,319 shares in the company, valued at approximately $7,674,737.03. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.20% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Iowa State Bank acquired a new position in shares of Eli Lilly and during the second quarter valued at $104,000. Tradewinds Capital Management LLC increased its position in shares of Eli Lilly and by 22.3% in the third quarter. Tradewinds Capital Management LLC now owns 1,345 shares of the company’s stock valued at $108,000 after buying an additional 245 shares during the period. PineBridge Investments L.P. increased its position in shares of Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock valued at $108,000 after buying an additional 920 shares during the period. Integrated Wealth Management increased its position in shares of Eli Lilly and by 3.7% in the third quarter. Integrated Wealth Management now owns 1,389 shares of the company’s stock valued at $112,000 after buying an additional 50 shares during the period. Finally, Financial Architects Inc increased its position in shares of Eli Lilly and by 4.5% in the third quarter. Financial Architects Inc now owns 1,423 shares of the company’s stock valued at $114,000 after buying an additional 61 shares during the period. Hedge funds and other institutional investors own 75.11% of the company’s stock.
Eli Lilly and Company Profile